Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TCF4 | P15884 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12933377 | 0.78 | BCHE (0.60) | RAB9ASMN1; SMN2LMNAALDH1A1TP53 | |
| SCHEMBL9979367 | 0.78 | ALPL (0.51) | IDO1ALPLALPIALPGMPO | |
| SCHEMBL12932937 | 0.77 | PDE10A (0.42) | RAB9AHTTALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL10220066 | 0.71 | ALDH1A1 (0.56) | IDO1ALPLALPIALPGSMN1; SMN2 | |
| SCHEMBL16188967 | 0.71 | IDO1 (0.60) | IDO1ALPLALPIALPGSMN1; SMN2 | |
| SCHEMBL10318988 | 0.69 | CYP3A4 (0.63) | IDO1ALPLALPIALPGRAB9A | |
| SCHEMBL12755406 | 0.69 | SCN10A (0.54) | RIPK1POLBMETAP2 | |
| SCHEMBL7590755 | 0.69 | ALDH1A1 (0.61) | IDO1ALPLALPIALPGRAB9A | |
| SCHEMBL29438978 | 0.69 | ALDH1A1 (0.61) | IDO1ALPLALPIALPGRAB9A | |
| SCHEMBL10271748 | 0.68 | IDO1 (0.66) | IDO1ALPLALPIALPGHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069322-A1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE FORMYLASE FOR TREATING MICROBIAL INFECTIONS | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2009-03-12 | — | — | US | disclosed |
| US-7173053-B2 | N-formyl hydroxylamine derivatives as inhibitors of bacterial polypeptide formylase for treating microbial infections | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2007-02-06 | — | — | US | disclosed |
| EP-1339400-B1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE DEFORMYLASE FOR TREATING MICROBIAL INFECTIONS | VERNALIS OXFORD LTD (GB) | 2005-06-29 | — | — | EP | disclosed |
| US-20040106666-A1 | Hydroxamic acid or n-formyl hydroxylamine derivatives as inhibitors of bakterial polypeptide deformylase for treating microbial infections | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2004-06-03 | — | — | US | disclosed |
| EP-1339400-A1 | HYDROXAMIC ACID OR N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE DEFORMYLASE FOR TREATING MICROBIAL INFECTIONS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002041886-A1 | YDROXAMIC ACID OR N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BAKTERIAL POLYPEPTIDE DEFORMYLASE FOR TREATING MICROBIAL INFECTIONS | BRITISH BIOTECH PHARMACEUTICALS LTD (GB) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069322-A1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE FORMYLASE FOR TREATING MICROBIAL INFECTIONS | FPR1, FPR3, FPR2 | IDO1 111/4885ALPL 4140/4885ALPI 2602/4885 |
| US-20040106666-A1 | Hydroxamic acid or n-formyl hydroxylamine derivatives as inhibitors of bakterial polypeptide deformylase for treating microbial infections | HNMT, ALKBH1, BAK1 | IDO1 887/4885ALPL 3507/4885ALPI 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.